- Condition Centers
Parenta Pharmaceuticals (West Columbia, SC), the US subsidiary of Austrian-based Ebewe Pharma, recently launched Vinorelbine Injection, USP. The product is the generic equivalent of GlaxoSmithKline's Navelbine. Vinorelbine Injection, USP is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non?small cell lung cancer (NSCLC). In patients with Stage IV NSCLC, the product is indicated as a single agent or in combination with cisplatin. In Stage III NSCLC, the product is indicated in combination with cisplatin. Vinorelbine Injection, USP is AP-rated, bar-coded, and latex-free and is supplied in 10-mg/mL and 50-mg/5 mL (10-mg/mL) single-dose vials. For more information, visit www.parentarx.com, or call 800-898-9948.
EPS Inc (Ivyland, PA) recently introduced EPS Oral Dispensers. The dispensers contain an innovative One-Piece Plunger construction that eliminates rubber grommets and silicone coating, facilitating an easy sliding of the plunger through the barrel. The dispensers are latex-free and contain graduations in both milliliters and fractionated teaspoon measurements. The EPS Oral Dispensers have a unique tip design, which makes for easier oral and topical dispensing applications. The tip design prohibits acceptance of hypodermic needles, and the low-capacity tip reservoir reduces residual content and ensures maximum delivery of medication. The dispensers can be capped with either Standard Tip Caps or Wagon Wheel stand design. The Wagon Wheel cap provides a solid base for standing dispensers on a countertop where they can be easily handled when administering medication. The product is available in 1-, 3-, 5-, and 10-mL sizes in either clear or ultraviolet-inhibitant amber. For more information, visit www.medidose.com, or call 800-523-8966.
American Regent Inc (Shirley, NY) recently launched Ketorolac Tromethamine Injection, USP. The product is indicated for the short-term management (<5 days) of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with intravenous (IV) or intramuscular (IM) dosing of ketorolac tromethamine. The product, which is AP-rated and latexfree, is available in 15 mg/1 mL and 30 mg/1 mL for IV/IM use, and 60 mg/2 mL for IM use only. For more information, visit www.americanregent.com, or call 800-645-1706.
CV Therapeutics Inc (Palo Alto, CA) and Astellas Pharma US Inc (Deerfield, IL) recently received FDA approval for Lexiscan Injection, an A2A adenosine receptor agonist. The product is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. The recommended dose of Lexiscan Injection is 5 mL (0.4 mg regadenoson) by rapid intravenous injection, followed immediately by saline flush and radiopharmaceutical. Clinicians should administer Lexiscan Injection as a rapid (approximately 10 seconds) injection into a peripheral vein using a 22-gauge-or-larger catheter or needle. Administer a 5-mL saline flush immediately after the injection of the product. Administer the radionuclide MPI agent 10 to 20 seconds after the saline flush. The radionuclide may be injected directly into the same catheter as Lexiscan Injection. The product is supplied as a single-use vial injection solution containing regadenoson 0.4 mg/5 mL and a single-use prefilled syringe injection solution containing regadenoson 0.4 mg/5 mL. For more information, visit www.lexiscan.com, or call 800-888-7704.
Find it Online
For more Hospital Product News, visit www.PharmacyTimes.com/HospitalProducts